Bio

John Oyler co-founded BeiGene, a fully-integrated, global biopharmaceutical company with a transformational mindset toward improving treatment outcomes and access for patients worldwide with cancer. Under his leadership, BeiGene has developed a number of promising compounds in its oncology pipeline that are being evaluated extensively in clinical trials throughout the world. BeiGene operates with a collaborative spirit to develop high-quality drugs faster, by harnessing the collective strength of U.S. drug development expertise with access to a large patient population in China. Cancer has no borders, and neither does BeiGene: the company has 3,000+ employees from Beijing to Basel.